Stafford-based Stroll, a digital therapeutic software company that uses augmented reality (AR) glasses to provide neurorehabilitation to patients living with neurological disorders has raised a €12.2 million Series A funding round.
The funding round was led by IW Capital, a leading investment house specialising in providing growth capital for UK SMEs.
Jorgen Ellis, CEO of Strolll said, “Strolll are at an exciting inflection point in our journey and we are delighted to be partnering with IW Capital, as well as other investment partners, as we look to accelerate the growth of our business.
“We are positioned at the forefront of the neurorehabilitation market and we’re passionate about helping to improve the care that patients with neurological disorders receive. We thank investors for believing in our vision of healthcare and we look forward to building on our achievements to date.”
Strolll was founded by Tom Finn in 2019, with Co-founder and CEO Jorgen Ellis joining in 2020. Ellis previously founded Flatpack Global at the age of 17, which he exited in 2019, having secured large partnerships with IKEA.
Strolll is disrupting the neurorehabilitation market with the “world’s first” clinically validated digital therapeutic software platform. The Strolll platform blends digital content with the real world through the use of off-the-shelf AR glasses and is aimed at helping people living with neurological disorders such as Parkinson’s disease, stroke, and Multiple Sclerosis.
Strolll enables patients to undergo therapy both within in-clinic and at-home settings, ensuring that patients can receive an increased dose of rehabilitation as compared to current standard care practices.
Strolll’s clinical trials have reportedly shown that clinicians using Strolll’s technologies are able to offer up to 7x more treatments with 67% less staff time. The technology has helped to improve mobility in patients who struggle to walk, balance or are at risk of falling.
Strolll’s technology helps patients by providing gamification of proven physiotherapy exercises. The games, of which there are currently seven, with more in the process of being developed, have been created using a clinician-led approach to game design to ensure maximum rehabilitation impact for patients.
Strolll’s solution enables clinicians to deliver personalised and high dosage immersive neurorehabilitation that stays in the real-world and improves treatment outcomes while reducing staffing requirements and administrative burdens.
Strolll will use the investment to accelerate its sales and marketing activities, extend its product leadership and to expand the regulatory label, which will allow Strolll to target additional neuro-related disorders adjacent to the ones it already addresses.
In July 2024, Strolll began a three-year, €2.8 million NIHR grant-funded project with the University of Leeds, University of York and 4 leading NHS trusts across the UK to conduct a randomised controlled trial of Strolll as a therapeutic treatment for patients with Parkinson’s disease in real-world healthcare settings.
In the same year, Strolll also entered the US market in a €2.7 million collaboration with US healthcare provider, Cleveland Clinic. This deal saw Cleveland Clinic transfer IP to Strolll in an exclusive software licensing agreement and become a shareholder in Strolll.
The investment from IW Capital into Strolll takes place against a backdrop of an aging global population and the increasing prevalence of neurological disorders such as Parkinson’s disease.
There have also been rapid enhancements in the Augmented Reality market, which was estimated to be €76.6 billion in 2024 – according to figures provided by Stroll. The market is expected to grow at a CAGR of 37.9% between 2025 and 2030 with the healthcare segment anticipated to record the fastest growth and to expand at a CAGR of 42.6% from 2023 to 2030.
Commenting on the investment, IW Capital’s Investment Director, Isobel Egemole, says, “IW Capital are thrilled to announce our investment into Strolll. Strolll are transforming the physiotherapy and neurorehabilitation markets and have already helped a significant number of people with debilitating neurological disorders to live better lives. The potential impact of their software is huge and we’re proud to be backing this cutting-edge business as it addresses key healthcare needs.”
Stroll received a total of €23.6 million of equity and grant funding to date, including this latest round of investment and currently employs 35 staff.
Read the orginal article: https://www.eu-startups.com/2025/03/neuro-rehab-software-startup-strolll-raises-e12-2-million-for-ar-glasses/
